<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">Finally, we evaluated the proportion of RSV-infected subjects who adequately received palivizumab-based prophylaxis before the onset of their ALRIs according to the 1999 marketing authorization of palivizumab by the European Medicines Agency (EMA) [
 <xref rid="bib11" ref-type="bibr">11</xref>], the 2007 guidelines of the French Health Authority (HAS), [
 <xref rid="bib8" ref-type="bibr">8</xref>] and the 2014 guidance for palivizumab use of the American Academy of Pediatrics (AAP) [
 <xref rid="bib12" ref-type="bibr">12</xref>].
</p>
